| Year |
Citation |
Score |
| 2021 |
Seaton KE, Deal A, Han X, Li SS, Clayton A, Heptinstall J, Duerr A, Allen MA, Shen X, Sawant S, Yates NL, Spearman P, Churchyard G, Goepfert PA, Maenza J, ... ... Morgan C, et al. Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines. 6: 56. PMID 33859204 DOI: 10.1038/s41541-021-00305-8 |
0.437 |
|
| 2020 |
Curlin ME, Shao J, Diaz G, Edlefsen PT, Novak RM, Mayer KH, Allen M, Morgan C, Maenza J, Buchbinder S, Keefer MC, Rosa SC, Corey L, Duerr A. Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine. PMID 32680773 DOI: 10.1016/J.Vaccine.2020.06.043 |
0.529 |
|
| 2020 |
Dietrich JJ, Hornschuh S, Khunwane M, Makhale LM, Otwombe K, Morgan C, Huang Y, Lemos M, Lazarus E, Kublin JG, Gray GE, Laher F, Andrasik M. A mixed methods investigation of implementation barriers and facilitators to a daily mobile phone sexual risk assessment for young women in Soweto, South Africa. Plos One. 15: e0231086. PMID 32324753 DOI: 10.1371/Journal.Pone.0231086 |
0.441 |
|
| 2020 |
Ditse Z, Mkhize NN, Yin M, Keefer M, Montefiori DC, Tomaras GD, Churchyard G, Mayer KH, Karuna S, Morgan C, Bekker LG, Mlisana K, Gray G, Moodie Z, Gilbert P, et al. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. Msphere. 5. PMID 31996422 DOI: 10.1128/mSphere.00738-19 |
0.463 |
|
| 2019 |
Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S, Swann E, Sobieszczyk ME, Frank I, Wilson GJ, Tieu HV, Maenza J, Norwood A, Kobie J, Sinangil F, et al. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. The Journal of Clinical Investigation. PMID 31566579 DOI: 10.1172/Jci128699 |
0.447 |
|
| 2019 |
Lazarus E, Otwombe K, Dietrich J, Andrasik MP, Morgan CA, Kublin JG, Gray GE, Isaacs AJ, Laher F. Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa. Southern African Journal of Hiv Medicine. 20: 866. PMID 31308962 DOI: 10.4102/Sajhivmed.V20I1.866 |
0.392 |
|
| 2019 |
Lemos MP, Lazarus E, Isaacs A, Dietrich J, Morgan C, Huang Y, Grove D, Andrasik M, Laher F, Hural J, Chung E, Dragavon J, Puren A, Gulati RK, Coombs R, et al. Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915). Journal of Acquired Immune Deficiency Syndromes (1999). 81: e39-e48. PMID 31095007 DOI: 10.1097/Qai.0000000000002015 |
0.402 |
|
| 2018 |
Auclair S, Liu F, Niu Q, Hou W, Churchyard G, Morgan C, Frahm N, Nitayaphan S, Pitisuthithum P, Rerks-Ngarm S, Kimata JT, Soong L, Franchini G, Robb M, Kim J, et al. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. Plos Pathogens. 14: e1006888. PMID 29474461 DOI: 10.1371/Journal.Ppat.1006888 |
0.475 |
|
| 2016 |
Lhomme E, Richert L, Moodie Z, Pasin C, Kalams SA, Morgan C, Self S, De Rosa SC, Thiébaut R. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. Plos One. 11: e0152952. PMID 27124598 DOI: 10.1371/Journal.Pone.0152952 |
0.485 |
|
| 2016 |
Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, Nitayaphan S, Pitisuttihum P, de Souza M, Duerr A, Morgan C, Gilmour JW. Adenovirus based HIV-1 vaccine candidates tested in efficacy trials elicit CD8 T-cells with limited breadth of HIV-1 inhibition. Aids (London, England). PMID 27088318 DOI: 10.1097/Qad.0000000000001122 |
0.515 |
|
| 2016 |
Deschamps MM, Metch B, Morgan CA, Zorilla CD, Donastorg Y, Swann E, Taina D, Patrice J, Pape WJ. Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907. Journal of Acquired Immune Deficiency Syndromes (1999). 71: 70-7. PMID 26761272 DOI: 10.1097/QAI.0000000000000796 |
0.399 |
|
| 2015 |
Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, et al. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. Journal of Aids & Clinical Research. 6. PMID 26587311 DOI: 10.4172/2155-6113.1000461 |
0.533 |
|
| 2015 |
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, et al. Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083). The Journal of Infectious Diseases. PMID 26475930 DOI: 10.1093/Infdis/Jiv496 |
0.542 |
|
| 2015 |
Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, ... ... Morgan C, et al. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science (New York, N.Y.). 349: aab1253. PMID 26229114 DOI: 10.1126/Science.Aab1253 |
0.521 |
|
| 2015 |
Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. Vaccine. 33: 2347-53. PMID 25820067 DOI: 10.1016/J.Vaccine.2015.03.036 |
0.527 |
|
| 2013 |
Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, Frank I. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. Journal of Acquired Immune Deficiency Syndromes (1999). 63: 239-44. PMID 23446497 DOI: 10.1097/Qai.0B013E31828Ded1A |
0.481 |
|
| 2013 |
Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, Nicosia A, Folgori A, Colloca S, Cortese R, Gostick E, ... ... Morgan C, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. Journal of Immunology (Baltimore, Md. : 1950). 190: 2720-35. PMID 23390298 DOI: 10.4049/Jimmunol.1202861 |
0.365 |
|
| 2013 |
Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G, Koblin B. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. Aids and Behavior. 17: 760-72. PMID 23090677 DOI: 10.1007/S10461-012-0351-6 |
0.456 |
|
| 2013 |
Day TA, Morgan CA, Kublin JG. Will mosaic vaccine immunogens expand immune response breadth to rival HIV-1 strain diversity? Clinical Investigation. 3: 413-415. DOI: 10.4155/Cli.13.29 |
0.557 |
|
| 2012 |
Kublin JG, Morgan CA, Day TA, Gilbert PB, Self SG, McElrath MJ, Corey L. HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. Clinical Investigation. 2: 245-254. PMID 23243491 DOI: 10.4155/Cli.12.8 |
0.461 |
|
| 2012 |
Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, et al. Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America. 109: E3503-12. PMID 23151505 DOI: 10.1073/Pnas.1208972109 |
0.514 |
|
| 2012 |
Fuchs J, Morgan C, Bart P, Kochar N, Frahm N, Swann E, Gilbert P, DeRosa S, Graham B, Nabel G, Liao H, Haynes B, Tomaras G. DNA and recombinant adenovirus serotype 35 and 5 preventive HIV-1 vaccines with Env A inserts elicit cross-clade binding and V1V2 antibodies Retrovirology. 9: 136. DOI: 10.1186/1742-4690-9-S2-P136 |
0.3 |
|
| 2012 |
Morgan C, Jin X, Yu X, Rosa SD, Kublin J, Metch B, Keefer M, Niaid H. DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials Retrovirology. 9: 133. DOI: 10.1186/1742-4690-9-S2-P133 |
0.532 |
|
| 2012 |
Koblin B, Metch B, Morgan C, Novak R, Swann E, Metzger D, Lucy D, Dunbar D, Graham P, Madenwald T, Escamia G, Frank I. Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906) Retrovirology. 9: 123. DOI: 10.1186/1742-4690-9-S2-P123 |
0.4 |
|
| 2012 |
Williams W, Jones K, Krambrink A, Grove D, Liu P, Yates N, Moody M, Ferrari G, Pollara J, Moodie Z, Morgan C, Liao H, Montefiori D, Ochsenbauer C, Kappes J, et al. Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial Retrovirology. 9. DOI: 10.1186/1742-4690-9-S2-O55 |
0.408 |
|
| 2011 |
Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R, et al. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. The Journal of Infectious Diseases. 204: 1541-9. PMID 21940420 DOI: 10.1093/Infdis/Jir615 |
0.407 |
|
| 2011 |
Koblin BA, Casapia M, Morgan C, Qin L, Wang ZM, Defawe OD, Baden L, Goepfert P, Tomaras GD, Montefiori DC, McElrath MJ, Saavedra L, Lau CY, Graham BS. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. Plos One. 6: e24517. PMID 21931737 DOI: 10.1371/Journal.Pone.0024517 |
0.492 |
|
| 2011 |
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). Plos One. 6: e21225. PMID 21857901 DOI: 10.1371/Journal.Pone.0021225 |
0.489 |
|
| 2011 |
De Rosa SC, Thomas EP, Bui J, Huang Y, deCamp A, Morgan C, Kalams SA, Tomaras GD, Akondy R, Ahmed R, Lau CY, Graham BS, Nabel GJ, McElrath MJ. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. Journal of Immunology (Baltimore, Md. : 1950). 187: 3391-401. PMID 21844392 DOI: 10.4049/Jimmunol.1101421 |
0.502 |
|
| 2010 |
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). Plos One. 5: e13579. PMID 21048953 DOI: 10.1371/Journal.Pone.0013579 |
0.525 |
|
| 2010 |
Cheng C, Gall JG, Nason M, King CR, Koup RA, Roederer M, McElrath MJ, Morgan CA, Churchyard G, Baden LR, Duerr AC, Keefer MC, Graham BS, Nabel GJ. Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. Journal of Virology. 84: 630-8. PMID 19846512 DOI: 10.1128/Jvi.00866-09 |
0.517 |
|
| 2008 |
Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, Flores J, Haigwood N, Hu SL, Johnson RP, Lifson J, Montefiori D, Moore J, Robert-Guroff M, Robinson H, et al. The use of nonhuman primate models in HIV vaccine development. Plos Medicine. 5: e173. PMID 18700814 DOI: 10.1371/Journal.Pmed.0050173 |
0.541 |
|
| 2003 |
Morgan CA, Lukehart SA, Van Voorhis WC. Protection against syphilis correlates with specificity of antibodies to the variable regions of Treponema pallidum repeat protein K. Infection and Immunity. 71: 5605-12. PMID 14500480 DOI: 10.1128/Iai.71.10.5605-5612.2003 |
0.519 |
|
| 2002 |
Morgan CA, Lukehart SA, Van Voorhis WC. Immunization with the N-terminal portion of Treponema pallidum repeat protein K attenuates syphilitic lesion development in the rabbit model. Infection and Immunity. 70: 6811-6. PMID 12438357 DOI: 10.1128/Iai.70.12.6811-6816.2002 |
0.533 |
|
| 2002 |
Morgan CA, Molini BJ, Lukehart SA, Van Voorhis WC. Segregation of B and T cell epitopes of Treponema pallidum repeat protein K to variable and conserved regions during experimental syphilis infection. Journal of Immunology (Baltimore, Md. : 1950). 169: 952-7. PMID 12097401 DOI: 10.4049/Jimmunol.169.2.952 |
0.511 |
|
| Show low-probability matches. |